These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study. Brener SJ; Kirtane AJ; Stuckey TD; Witzenbichler B; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Mehran R; Parvataneni R; Brodie BR; Stone GW JACC Cardiovasc Interv; 2016 Jul; 9(14):1450-7. PubMed ID: 27372190 [TBL] [Abstract][Full Text] [Related]
33. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting. Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635 [TBL] [Abstract][Full Text] [Related]
34. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669 [TBL] [Abstract][Full Text] [Related]
35. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Coons JC; Seybert AL; Saul MI; Kirisci L; Kane-Gill SL Ann Pharmacother; 2005 Oct; 39(10):1621-6. PubMed ID: 16105872 [TBL] [Abstract][Full Text] [Related]
36. Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Schweiger MJ; Changezi HU; Naglieri-Prescod D; Cook JR Clin Ther; 2003 Jan; 25(1):225-34. PubMed ID: 12637122 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of abciximab in older adults undergoing percutaneous coronary intervention. Brown RA; Shantsila E; Varma C; Lip GY Int J Clin Pract; 2015 Nov; 69(11):1334-40. PubMed ID: 26202207 [TBL] [Abstract][Full Text] [Related]
38. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. McCollam PL; Foster DA; Riesmeyer JS Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921 [TBL] [Abstract][Full Text] [Related]
39. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720 [TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Brown DL; Fann CS; Chang CJ Am J Cardiol; 2001 Mar; 87(5):537-41. PubMed ID: 11230835 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]